Latest Commercialization News

BrainChip Holdings has bolstered its financial position with a A$35 million capital raise and commenced volume production of its AKD1500 neuromorphic AI chip, while deepening its strategic partnership with Parsons’ defence arm.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

OD6 Metals has reported significant progress in its rare earth and copper projects, unveiling a high-recovery processing flowsheet and identifying promising new copper conductors near historic workings.

BetMakers Technology Group reported a robust Q2 FY26 with positive adjusted EBITDA and significant contract wins poised to fuel growth in the second half of the year.

6K Additive reported a strong finish to 2025 with a 25% revenue jump in Q4 and secured $31.4 million in IPO proceeds to fuel a fivefold production expansion. The company also landed a $27.4 million US government-backed loan, positioning it for accelerated growth in the additive manufacturing sector.

Galan Lithium has raised A$40 million through an institutional placement to expand production at its Hombre Muerto West project by 30%, aiming for first lithium output in the first half of 2026.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Horizon Oil reported an 18% rise in production and sales volumes in Q2 FY26, driven by its first full quarter of Thailand asset output. The company also maintained strong cashflow, paid a final FY25 dividend, and secured a long-term gas supply agreement in Australia’s Northern Territory.

D3 Energy has reported encouraging progress in its South African helium and methane operations, highlighted by improved gas flow rates from the Nooitgedacht Major well and an upgraded US OTCQX listing to broaden investor reach.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.